Dengue virus type 4 pre-membrane protein (prM)

The Dengue virus type 4 pre-membrane protein (prM) is a critical structural component of the Dengue virus (DENV-4) virion. Its primary biological role is to act as a chaperone for the Envelope (E) protein during viral assembly within the endoplasmic reticulum, preventing the E protein from undergoing premature acid-induced conformational changes during transport through the secretory pathway (UniProt: P09866). During the final stages of viral maturation, the prM protein is cleaved by the host cell protease furin into the 'pr' peptide and the mature 'M' membrane protein, a step essential for the virus to become infectious (PubMed: 18275812). In the context of disease, prM is a major target for the host immune system; however, antibodies directed against prM are often cross-reactive across different DENV serotypes and frequently lack strong neutralizing activity. This characteristic is a significant concern in dengue pathology as such antibodies can facilitate antibody-dependent enhancement (ADE), potentially leading to more severe forms of the disease like Dengue Hemorrhagic Fever (PubMed: 20448183). In drug development, prM is a core component of several live-attenuated and chimeric vaccines, such as Dengvaxia and Qdenga, which utilize the prM and E protein sequences to elicit protective immunity (NIH: NCT00384670).

Other names

Precursor membrane proteinMembrane glycoprotein precursorprM proteinDENV-4 prM

Induction of humoral immune response and neutralizing antibodies against the structural components of the virus to prevent viral entry and replication.